As shown in Table 1 and S2 Fig, untreated parasite cultures and cultures treated with dasatinib, i.e. a broad spectrum tyrosine kinase inhibitor (TKI) that suppresses the activities of bcr-abl, src, lck, yes, fyn, lyn, hck, c-kit, EPHA2, and PDGFRβ displayed an unabated increase in parasitemia, demonstrating that dasatinib can neither prevent parasite egress nor block P. falciparum reinvasion/proliferation in fresh human RBCs. Here, LYN is linked to parasitic infectious disease.